BioCentury

8:00 AM GMT, Dec 5, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Lucentis ranibizumab regulatory update

The U.K.'s NICE issued final guidance recommending against Lucentis ranibizumab from Novartis to treat diabetic macular edema (DME). The committee said Novartis did not provide a "true reflection" of Lucentis' cost-effectiveness compared with laser photocoagulation, the standard of care. NICE concluded that the incremental cost-effectiveness

Read the full 452 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.